Skip to main content
SpringerLink
Log in

New therapeutic approaches in sepsis: A critical review

  • Original
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

This paper reviews several recent, randomized, double-blind, placebo-controlled trials of monoclonal antibodies against endotoxin, interleukin-1 receptor antagonist (IL-1 ra), and monoclonal antibody against tumor necrosis factor (TNF) in sepsis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sprung CL, Caralis PV, Marcial EH et al (1984) The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 311:1137–1143

    Google Scholar 

  2. Bone RC, Fisher CJ Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med 317:653–658

    Google Scholar 

  3. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effects of high-dose glucocorticoid therapy of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665

    Google Scholar 

  4. Ziegler EJ, McCutchan JA, Fierer J et al (1987) Treatment of gram-negative bacteremia and shock with human antiserum to a mutantEscherichia coli. N Engl J Med 307:1225–1290.

    Google Scholar 

  5. Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436

    Google Scholar 

  6. Greenman RL, Schein RMH, Martin MA et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 266: 1097–1102

    Google Scholar 

  7. Wenzel R, Bone R, Fein A et al (1991) Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody E 5 in Gram negative sepsis. In: Program and Abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy. 29 September–2 October, Chicago: 294

  8. Fisher CJ, Dhainaut JFA, Opal SM et al (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836–1843

    Google Scholar 

  9. McCloskey RV, Straube RC, Sanders C et al (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1–5

    Google Scholar 

  10. Wherry J, Wenzel R, Wunderink R et al (1993) Monoclonal antibody to human tumor necrosis factor (TNF MAb): multi-center efficacy and safety study in patients with the sepsis syndrome. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orelans, 17–20 October 1993, Washington, D. C.: American Sciety for Microbiology: 696, abstract

    Google Scholar 

  11. Baumgartner JD, Glauser MP, McCutchan JA et al (1985) Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet II:59–63

    Google Scholar 

  12. Calandra T, Glauser MP, Schellekens J et al (1988) Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J 5: A prospective, double-blind, randomized trial. J Infect Dis 158:312–319

    Google Scholar 

  13. Dunn DL, Ewald DC, Chandan N et al (1986) Immunotherapy of Gram-negative bacterial sepsis: A single murine monoclonal antibody provides crossgenera protection. Arch Surg 121: 58–62

    Google Scholar 

  14. Teng NNH, Kaplan HS, Herbert JM et al (1985) Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794

    Google Scholar 

  15. Wortel CH, von der Mohlen MAM, van Deventer SJH et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (Ha-1A) in Gram-negative sepsis. Relationship to endotoxin and cytokine levels. J Infect Dis 166: 1367–1374

    Google Scholar 

  16. Siegel JP, Stein KE, Zoon KC (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 327:890–891

    Google Scholar 

  17. Fisher CJ Jr, Slotman GJ, Opal SM et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled, multicenter trial. Crit Care Med 22:12–21

    Google Scholar 

  18. Eidelman LA, Sprung CL (1994) Why have new effictive therapies for sepsis not been developed? Crit Care Med 22: 1330–1334

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology/Critical Care Medicine, Hadassah Hebrew University Medical Center, P.O. Box 12000, 91120, Jerusalem, Israel

    L. A. Eidelman, R. Pizov & C. L. Sprung

Authors
  1. L. A. Eidelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Pizov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. L. Sprung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eidelman, L.A., Pizov, R. & Sprung, C.L. New therapeutic approaches in sepsis: A critical review. Intensive Care Med 21 (Suppl 2), S269–S272 (1995). https://doi.org/10.1007/BF01740766

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01740766

Key words

Search

Navigation